Immuron Ltd has released a press release.
IMC Preclinical Study Reports Reduction in Colitis Symptoms
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Travelan Sales Continue to Soar in Third Quarter of FY2018
- Immuron Announces A$5.1M Private Placement to U.S. Fund
- Immuron Reports Positive Results in NASH Clinical Trial
- Correction to False and Misleading News Release
- Appendix 4D - Half Year Financial Report - 31 Dec 2017
Later from Immuron
- Immuron Announces Board Appointment
- European Patent Gramted for Nash Treatment
- US Department of Defense Research Collaboration Moves Ahead
- Immuron Reports Record Revenue
- US DoD Report Travelan Protects Against Shigella in Primates
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron